China, U.S. consumer protection MOU
This article was originally published in The Tan Sheet
Executive Summary
As FDA and other agencies continue tests to determine whether bulk food and drug ingredients from China are contaminated, the Federal Trade Commission announces a memorandum of understanding with its Chinese counterpart to promote consumer protection cooperation. The non-binding MOU, which covers all products including drugs and dietary supplements, comes after FTC and China's State Administration for Industry and Commerce began work on consumer protection issues. "This is sort of a formal strengthening of the relationship that we agreed," says Jackie Dizdul, of FTC's Office of Public Affairs. FDA has ordered the detention without physical examination of all dentifrice products including aerosols, liquids, toothpastes and tooth powders with or without fluoride containing diethylene glycol after a sampling assignment discovered DEG in several Chinese products (1"The Tan Sheet" June 4, 2007, In Brief)
You may also be interested in...
Chinese toothpaste import alert
FDA warns consumers not to use toothpaste labeled as made in China and issues an import alert June 1 to prevent toothpaste containing toxic diethylene glycol from entering the country. One shipment of toothpaste containing 3% DEG has been identified and detained at the U.S. border by agency inspectors, and DEG-containing toothpaste also was found at a distribution center and a retail store, FDA states. No U.S. incidents of poisoning from toothpaste adulterated with DEG have been reported, according to the agency. Panama's health ministry also recently found DEG in Chinese-manufactured toothpastes, which in part contributed to FDA's increased scrutiny of toothpaste and other dental products made in China, FDA says (1"The Tan Sheet" May 28, 2007, In Brief)...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.